Our report suggests that for patients with cardiomyopathy accompanied by elevated CK levels, the possibility of neutral lipid storage disease should be considered, and the PNPLA2 gene should be considered for inclusion in cardiomyopathy genetic panels. The gene discussed is PNPLA2; the disease is cardiomyopathy.